Pharmazz
WILLOWBROOK, Illinois · Biotechnology, Healthcare, Health Care
Pharmazz is a privately held company developing novel products in critical care medicine. The U.S. Food and Drug Administration (FDA) has approved two phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for cerebral ischemic stroke. In addition, Pharmazz obtained marketing authorization for two of its first-in-class drug molecules, Centhaquine and Sovateltide, for hypo
Key facts
- Headquarters
- WILLOWBROOK, Illinois
- Employees
- 51
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- pharmazz.com
- Company page
Recent activity at Pharmazz
Pharmazz funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Venture | $250K |
| Jun 2025 | Venture | $10.0M |
| Aug 2024 | Venture | $7.5M |
| Feb 2024 | Seed | $150K |
| Nov 2023 | Seed | $450K |
Leadership
- Manish, Managing Director
- Anil Gulati, Executive Officer, Director
- Ajit Srimal, Executive Officer, Director
- James McDonnell, Director
- Ajit Srimal, Director
- Anil Gulati, Executive Officer, Director
- Ajit Srimal, Director
- Anil Gulati, Executive Officer, Director
- Anil Gulati, Executive Officer, Director
- Sunil Gulati, Executive Officer
- David Costello, Executive Officer
- Guru Reddy, Executive Officer
Verified email and direct lines for Pharmazz’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Pharmazz in the news
- Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate - GlobeNewswire (Sep 30, 2026)
- Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd. - Yahoo Finance (Jun 11, 2025)
- Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke - Yahoo Finance (Sep 28, 2026)
- Sun Pharma to invest $25 million in US biopharmaceutical company Pharmazz Inc - BusinessLine (May 25, 2025)
- Sun Pharma and Pharmazz ink agreement for introducing Tyvalzi in India - Indian Pharma Post (Sep 15, 2023)
- Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officer - GlobeNewswire (May 14, 2026)
- Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) - Yahoo Finance (Sep 14, 2026)
- Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients - GlobeNewswire (May 31, 2023)
Companies similar to Pharmazz
- Avalyn · Biotechnology, Healthcare, Health Care
- Beyond Air · Biotechnology, Healthcare, Health Care
- Omniscient Neurotechnology · Biotechnology, Healthcare, Health Care
- Shape Memory Medical · Biotechnology, Healthcare, Health Care
- Enlaza Therapeutics · Biotechnology, Healthcare, Health Care
About Pharmazz: questions and answers
What does Pharmazz do?
Pharmazz is a privately held company developing novel products in critical care medicine. The U.S. Food and Drug Administration (FDA) has approved two phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for cerebral ischemic stroke. In addition, Pharmazz obtained marketing authorization for two of its first-in-class drug molecules, Centhaquine and Sovateltide, for hypo
Where is Pharmazz headquartered?
Pharmazz is headquartered in WILLOWBROOK, Illinois.
How many employees does Pharmazz have?
Pharmazz has about 51 employees.
Has Pharmazz raised funding?
Yes. Fundz has recorded 5 funding events for Pharmazz. The most recent, $250K, was in Jul 2026.
What is the latest news on Pharmazz?
On Jul 28, 2026, Pharmazz
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy